[Billing Code: 4140-01-P]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Allergy and Infectious Diseases Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby
given of the following meeting.
The meeting will be closed to the public in accordance with the provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the
discussions could disclose confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated with the contract proposals,
the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis
Panel NIAID Research Topic No. 051 Inhaled Delivery of Clofazimine (CFZ) – An Important
Anti-Tuberculosis Drug Phase II Proposal Title: Optimized Dry Powder Formulation and
Delivery for Inhaled Clofazimine (N01)
Date: January 27, 2022
Time: 1:00 PM to 3:00 PM
Agenda: To review and evaluate contract proposals
Place: National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 3G31
Rockville, MD 20892
(Virtual Meeting)
Contact Person: Cynthia L. De La Fuente, PHD
Scientific Review Officer
Scientific Review Program
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
National Institutes of Health
5601 Fishers Lane, Room 3G31
Rockville, MD 20852
240-669-2740
delafuentecl@niaid.nih.gov
(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and
Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National
Institutes of Health, HHS)
Dated: December 30, 2021.
Tyeshia M. Roberson-Curtis,
Program Analyst,

Office of Federal Advisory Committee Policy.
[FR Doc. 2022-00008 Filed: 1/5/2022 8:45 am; Publication Date: 1/6/2022]